There were no limiting safety or tolerability signals identified with the addition of valganciclovir to pirfenidone therapy in patients with idiopathic pulmonary fibrosis.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Lower percent predicted forced vital capacity may serve as an independent predictive factor for adverse outcomes in patients with interstitial lung disease and microscopic polyangiitis.
Ziritaxestat is an investigational autotaxin inhibitor.
A self-reported family history of pulmonary fibrosis (PF) is predictive of decreased transplant-free survival in patients with idiopathic PF (IPF) and in those with non-IPF interstitial lung disease.
Patients with idiopathic pulmonary fibrosis (IPF) have nearly double the risk of having gastroesophageal reflux disease (GERD) compared with the general population.
Persistent inflammatory interstitial lung disease has been observed among patients following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Patients with pulmonary hypertension caused by interstitial lung disease experienced greater improvements in exercise capacity with inhaled treprostinil compared with placebo.
The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.
Trimethoprim-sulfamethoxazole therapy did not reduce time to death, lung transplant, or hospitalization in patients with moderate or severe idiopathic pulmonary fibrosis.
